Shannon L. Puhalla, MD
Researchers are seeking to determine whether adding the PARP inhibitor veliparib to a chemotherapy combination will improve outcomes for patients with HER2-negative, germline BRCA
-associated metastatic or locally advanced breast cancer.
The Brocade 3 trial is being conducted by AbbVie, which is also the company developing the drug. The study is expected to be completed in March 2018.
- BRCA1 and BRCA2: cancer risk and genetic testing. National Cancer Institute website. https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet#q2. Updated April 1, 2015. Accessed December 30, 2016.
- Han HS, Diéras V, Robson M, et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Presented at: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, TX. Abstract S2-05.
... to read the full story